MOSHE TALPAZ MD
Prescription History 1801972773
Internal Medicine - Medical Oncology in Ann Arbor, MI
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MOSHE TALPAZ MD, an active Medical Oncology specialist practicing in Ann Arbor, MI. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 112 documented patient claims. Among these therapy options, the most frequently utilized medication is Jakafi, which accounts for 40 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2024)Rx (2024) | Avg Cost per FillCost / Fill | Vs. Other MI PrescribersVs. MI Avg |
|---|---|---|---|
| JakafiRuxolitinib Phosphate | 40 | $14,821.30▼ below MI avg | ≈ Typical |
About Jakafi: This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). Show more ▾ It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system). In 2024, this provider wrote 40 Medicare prescriptions for Jakafi, about 1.2 times the volume of the typical Michigan prescriber of this medication (32.1). Medicare paid an average of $14,821.30 per fill, versus $15,567.52 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average MI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MI average for this medication. 40 30-Day Fills standardized to 30-day supplies 1,200 Days of Medication total across all patients in 2024 | |||
| Hydroxyurea | 31 | $22.74▼ below MI avg | ≈ Typical |
About Hydroxyurea: This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Show more ▾ Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas). An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. In 2024, this provider wrote 31 Medicare prescriptions for Hydroxyurea, about 75% of the volume of the typical Michigan prescriber of this medication (41.1). Medicare paid an average of $22.74 per fill, versus $30.68 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average MI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MI average for this medication. 64.5 30-Day Fills standardized to 30-day supplies 1,921 Days of Medication total across all patients in 2024 | |||
| PegasysPeginterferon Alfa-2a | 17 | $3,069.80▼ below MI avg | ≈ Typical |
About Pegasys: Peginterferon alfa-2a is used alone or in combination with other medications to treat chronic hepatitis B and chronic hepatitis C, viral infections of the liver. Show more ▾ It works by decreasing the amount of hepatitis virus in the body and helps your body's natural defense (immune system) fight the infection. Chronic hepatitis infection can lead to serious liver damage (cirrhosis) and liver cancer. It is not known if peginterferon can cure hepatitis B or hepatitis C infections or can prevent you from passing the virus to others. Practice "safer sex" (such as the use of latex condoms) to lower the risk of passing the virus to others. Interferon alfa-2A chemically modified by the covalent attachment of a polyethylene glycol. In 2024, this provider wrote 17 Medicare prescriptions for Pegasys, about 76% of the volume of the typical Michigan prescriber of this medication (22.4). Medicare paid an average of $3,069.80 per fill, versus $3,606.78 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average MI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MI average for this medication. 17 30-Day Fills standardized to 30-day supplies 476 Days of Medication total across all patients in 2024 | |||
| ScemblixAsciminib Hydrochloride | 13 | $38,803.99 | ▼ Less than typical |
About Scemblix: Asciminib is used to treat a certain type of cancer (chronic myeloid leukemia-CML). Show more ▾ Asciminib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Inhibits ABL1 protein. In 2024, this provider wrote 13 Medicare prescriptions for Scemblix, about 70% of the volume of the typical Michigan prescriber of this medication (18.6). Medicare paid an average of $38,803.99 per fill, versus $26,011.64 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average MI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 13 30-Day Fills standardized to 30-day supplies 324 Days of Medication total across all patients in 2024 | |||
| Deferasirox | 11 | $64.86▼ below MI avg | ▼ Less than typical |
About Deferasirox: This medication is used to treat ongoing high levels of iron in the body caused by multiple blood transfusions. Show more ▾ It is also used to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions (non-transfusion-dependent thalassemia). It works by binding to iron, allowing the body to pass extra iron out in the stool. Deferasirox belongs to a class of drugs known as iron-chelating agents. Frequent blood transfusions are often needed in certain types of blood diseases (such as sickle cell disease, anemia). Blood transfusions have very helpful benefits, but they can cause the body to hold on to too much iron. The extra iron can build up in the body and cause problems such as heart failure, liver disease, and diabetes. Getting rid of extra iron can decrease the risk of these diseases. A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA. In 2024, this provider wrote 11 Medicare prescriptions for Deferasirox, about 65% of the volume of the typical Michigan prescriber of this medication (17). Medicare paid an average of $64.86 per fill, versus $1,640.62 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average MI prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the MI average for this medication. 11 30-Day Fills standardized to 30-day supplies 330 Days of Medication total across all patients in 2024 | |||
About this data. The prescription history for MOSHE TALPAZ MD is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2024, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Medical Oncology prescribing approach at this Ann Arbor, MI practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average among MI prescribers of the same medication and form, shown only when at least five prescribers contribute. Always confirm current medications and costs directly with the provider and your plan.
About the medication summaries. Drug use descriptions come from the CMS Medicare Part D Drug Spending Dashboard (2024), and substance definitions from Medical Subject Headings (MeSH) 2026, U.S. National Library of Medicine. They are summaries that do not contain all possible information about a medication and are not individual medical advice. Ask a health care professional about any medication and your specific health needs.
